Before I begin my story, I would like to do a simple activity with everyone in this room. Start again. >> All right.I would I want to invite everyone to stand up. I'm going to give you three statements and every time your answer to the statement is a yes. You remain standing.If it's a no, you can sit down. Okay, first statement. I am familiar with the word neurode divergent.It's a no. You may sit down. Second statement.I know someone who is a neurode divergent. Okay. And the last statement, I am a neurodyiv ...

When psychologist Thomas Brown started seeing students, he suspected they might be suffering from ADHD. But it carried a stigma, and parents resisted the diagnosis—and medication. https://t.co/rbTfGsJ5TM ...

Hi, my name is Sophia Fuks. I am neurody divergent and I would like to tell you how to understand neurodiversity and why we should support it. First of all, a lot of you guys may be asking, "Oh, Sophia, what on earth is neurodeiversity?" Well, let me explain.Neurode diversity is defined as the concept that not all brains are the same and that we all have different ways of thinking. Adding on to that, a person who is neurode divergent has different brain wiring. So think someone with ADHD, autism, Tourette's ...

Functional Vision Problems & Impact - Functional vision problems are distinct from eyesight, impacting how the brain processes visual information [2][3] - These issues can manifest as difficulties in reading, learning, and daily life activities, often misdiagnosed as ADD, ADHD, dyslexia, or autism spectrum disorders [6][7][9] - Vision directs behavior; impaired eye control hinders mind control and focus [8] Modern Visual Demands - The visual system, evolved for distance viewing, struggles with modern near-screen demands [11][12] - Reading and learning are significantly impacted, with an estimated 80% of classroom learning relying on visual processing and one in four children experiencing vision problems affecting learning [12] - Screen time contributes to digital eye strain, affecting at least 60% of Americans [15] Vision Performance Training - Vision performance training can treat functional vision problems by rewiring the brain's software [10][19] - It helps develop neurological pathways for accurate eye movements and efficient visual information processing [25] Traumatic Brain Injury - 28% of Americans have experienced at least one concussion, potentially impacting vision [20] - Head injuries can lead to vision problems, even without affecting eyesight, due to the brain's heavy reliance on visual processing (two-thirds of neurons originate from the eyes) [21]

Inspiration & Creativity - The talk explores the journey of Liang Yaxin (Cat Lost Module) from being labeled as "not good enough" due to ADHD to becoming an independent artist [1] - It emphasizes embracing imperfections and releasing unique creativity [1] Personal Growth & Self-Acceptance - The narrative highlights a journey of self-acceptance and overcoming challenges associated with ADHD [1] Event Information - The talk was presented at a TEDx event, independently organized by a local community [1]

Public-health officials may have preferred a little more nuance in the president’s explanation of a potential link between Tylenol and autism and ADHD. We explain what he left out https://t.co/NjUQKeBxgy ...

Investment Philosophy & Strategy - A16Z views technology as a unifying force across various sectors, including gaming, crypto, and American Dynamism, emphasizing their interconnectedness and shared foundations in technological progress [2] - The firm emphasizes the importance of the "Techno Optimist Manifesto" as a coherent thesis underlying all building and innovation, highlighting the universal journey of founders across different sectors [1] - A16Z sees crypto as a freedom-promoting technology that complements American values by providing mechanisms for capital movement, property rights, and free payments, especially in scenarios where America may not be freedom-promoting [2] - The company recognizes the philosophical alignment between founders in crypto and American Dynamism, noting their shared understanding of America's problems and the need for building solutions [2] Industry Trends & Observations - The discussion highlights a shift in how the current generation understands medicine, with the internet becoming a primary source of information and individuals actively engaging with medical data and seeking second opinions [3][4] - The report notes a potential over-diagnosis of ADHD in young boys, with 23% of 17-year-old boys in America receiving such a diagnosis, raising questions about the incentives driving these diagnoses [6] - The analysis points out the fragmentation of internet culture, with isolated pockets forming around specific interests like gaming, making it difficult for outsiders to understand their nuances [56][58] - X (formerly Twitter) is identified as a unifying platform and a valuable source of ground truth due to its open graph, dialogical nature, and the presence of a generation adept at translating across different platforms [61][64][71] Societal & Cultural Commentary - The discussion touches on the increasing opportunity cost of having children due to career aspirations and international travel, as well as the decline of the multigenerational family unit, which traditionally provided support for childcare [41][42] - The report reflects on the reactions to the Charlie Kirk assassination, highlighting a gap between Zoomer culture and mainstream understanding, emphasizing the need to recognize the diversity and unintelligibility of online cultures [49][55] - The company acknowledges the potential benefits of boredom and exposure to diverse perspectives in traditional schooling, suggesting that these experiences can be valuable for children's development [32][33]

Summary of Aytu Biopharma Conference Call Company Overview - Aytu Biopharma is a specialty pharmaceutical company founded in 2015, focusing on ADHD and pediatric products, with a revenue of approximately $66 million, of which $58 million is from ADHD products [4][5] - The company has a program called Aytu Rx Connect, partnering with 1,000 pharmacies to ensure patients have access to prescriptions at a maximum cost of $50 [6] New Product Launch - Aytu Biopharma is preparing to launch a new product, ExuA, for major depressive disorder (MDD), which is a $22 billion market [8] - ExuA is a novel treatment that targets the 5-HT1A receptor, differentiating it from existing SSRIs and SNRIs that often cause side effects like sexual dysfunction and weight gain [9][10] - The product is expected to launch by December 2025, with initial sales to wholesalers and a more significant revenue impact anticipated by June 2026 [32] Market Dynamics - The MDD market sees 340 million prescriptions annually in the U.S., with SSRIs and SNRIs accounting for about 60% of these [12] - Competitors like Trintellix, Avelity, and Spravato have seen growth but share similar side effects that ExuA aims to avoid [13][14] - Government payers are required to cover depression treatments, which could account for 30-40% of the market for ExuA [19] Financial Performance - For the fiscal year 2025, Aytu reported $66.4 million in revenue and an adjusted EBITDA of $9.2 million, marking three consecutive years of positive adjusted EBITDA [36] - The company raised $15 million in June 2025 to support the launch of ExuA, with a cash balance of $31 million as of June 30, 2025 [39][40] Strategic Initiatives - Aytu is focusing on refining sales territories and engaging with psychiatrists, as 60% of their current psychiatrist contacts overlap with the target market for ExuA [18] - The company is also working on branding and promotional strategies to effectively communicate the benefits of ExuA to clinicians [20] Investor Outlook - The management believes ExuA could quickly become a $50 million business within a year of launch, based on the number of prescriptions and the product's unique selling points [42] - The company is exploring ways to extend the patent life of ExuA, which currently has a five-year runway [52][53] Key Takeaways - Aytu Biopharma is positioned for growth with the upcoming launch of ExuA, targeting a significant market opportunity in MDD while leveraging its existing ADHD business [5][8] - The company has a solid financial foundation and strategic plans in place to maximize the potential of its new product [36][39]

Financial Data and Key Metrics Changes - For fiscal year 2025, net revenue was $66.4 million, a slight increase from $65.2 million in the previous year [28] - Adjusted EBITDA for the year was $9.2 million, marking the third consecutive year of positive adjusted EBITDA, down from $10.8 million in the prior year [34][33] - Gross margin decreased to 69% from 75% in the previous year, primarily due to increased cost of sales in ADHD inventory [29][30] Business Line Data and Key Metrics Changes - ADHD portfolio net revenue was $57.6 million, slightly down from $57.8 million, attributed to a decrease in the number of prescriptions written [28] - Pediatric portfolio revenue increased to $8.8 million from $7.3 million, reflecting a successful return-to-growth plan [29] Market Data and Key Metrics Changes - The U.S. market for major depressive disorder (MDD) is over $22 billion, with Exua targeting a significant portion of this market [7][9] - SSRIs and SNRIs represent over 60% of all antidepressants prescribed, indicating a competitive landscape for Exua [9][10] Company Strategy and Development Direction - The company is focusing on the launch of Exua, a novel treatment for MDD, which is expected to transform its business model [4][7] - Aytu BioPharma plans to leverage its psychiatry-focused sales force and proprietary patient access platform to drive product acquisitions aligned with its focus [6][19] - The company aims to minimize coverage barriers and enhance patient access through strategic payer contracting [17][52] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming launch of Exua, highlighting positive feedback from psychiatrists regarding the product [41][43] - The company anticipates that the Exua launch will position it as one of the fastest-growing CNS-focused companies in the industry [44] Other Important Information - The company has launched an authorized generic of Adzenys to maintain market share amid potential competition from Teva [21] - Aytu BioPharma has successfully raised $16.6 million through a public offering to support the Exua launch [35] Q&A Session Summary Question: Will there be a national sales meeting for Exua? - Management confirmed that a sales meeting is planned before the full launch in the first calendar quarter of 2026 [47] Question: Will promotional materials be pre-cleared? - Management stated they do not plan to pre-clear promotional materials but will follow the traditional submission process [48] Question: What is the strategy for engaging with payers? - Management indicated a selective approach to payer engagement, focusing on ensuring favorable contracting without undermining margins [50][52] Question: What are the expectations for ADHD and pediatric portfolio contributions? - Management expects the ADHD and pediatric portfolios to cover general and administrative expenses, with a break-even target of approximately $13 million quarterly [60][62] Question: What is the medical affairs strategy for Exua? - Management outlined plans for extensive medical affairs efforts, including presentations at medical conferences and educational programs [63]

Neurodiversity & Self-Awareness - The discussion revolves around the complexities of self-awareness, particularly in the context of neurodivergence (autism and ADHD) [1][3][19] - The speaker shares their personal journey of being diagnosed with autism and ADHD, highlighting the initial lack of understanding and the later challenges faced in college [2][3][7] - The presentation explores the dual nature of self-awareness, acknowledging its potential for growth and adaptation while cautioning against the pitfalls of excessive self-criticism [17][18] Challenges & Coping Mechanisms - The speaker describes the difficulties encountered in college due to ADHD, including disorganization, attention dysregulation, insomnia, and executive dysfunction [8][9][11] - The narrative addresses the internal conflict between past achievements and current struggles, leading to feelings of incompetence and laziness [9][10] - The speaker emphasizes the importance of seeking help from peers, professors, parents, and psychiatrists to manage the challenges associated with neurodivergence [13] Impact of Diagnosis - The diagnosis of autism and ADHD is not portrayed as a simple solution but rather as a starting point for self-understanding and adaptation [19][20] - The speaker notes that increased self-awareness can sometimes lead to heightened self-consciousness and overthinking of social interactions [14][15] - The presentation advocates for a balanced approach to self-awareness, encouraging self-understanding without succumbing to self-doubt and negative self-criticism [18]